Long-term outcomes of an advanced hybrid closed-loop system: A focus on different subpopulations

Background: The long-term benefit provided by advanced hybrid closed-loop (AHCL) systems needs to be assessed in general populations and specific subpopulations.Methods: A prospective evaluation of subjects initiating the AHCL system 780G was performed. Time in range (70-180 mg/dl) (TIR), < 70 mg/dl, < 54 mg/dl, > 180 mg/dl and > 250 mg/dl were compared, at baseline and after one year, in different subpopulations, according to previous treatment (pump vs MDI), age (> or & LE;25 years old) and hypoglycaemia risk at baseline.Results: 135 subjects were included (age: 35 +/- 15 years, 64 % females, diabetes duration: 21 +/- 12 years). An increase in TIR was found, from 67.26 +/- 11.80 % at baseline to 77.41 +/- 8.85 % after one year (p < 0.001). All the subgroups showed a significant improvement in TIR, time > 180 mg/dl and > 250 mg/dl. At the 1-year evaluation, no significant differences were found, between previous pump users and MDI subjects. Children and young adults had a lower time < 70 mg/dl than adults. Subjects with a high risk of hypoglycaemia at baseline had a higher time spent at < 70 mg/dl and < 54 mg/dl than low-risk individuals.Conclusion: The initial benefit provided by the AHCL system is sustained in the long term. MDI subjects obtain the same outcomes as subjects with pump experience.

Automated summary

This study prospectively evaluated the long-term benefit of using the advanced hybrid closed-loop system (AHCL) in different subpopulations. The results showed sustained improvement in blood glucose control and hypoglycemia risk with the AHCL system in all subgroups.